This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sumethkul, V Articles by Radinahamed, P Search for Related Content PubMed PubMed Citation Articles by Sumethkul, V Articles by Radinahamed, P Social Bookmarking                         What's this?

Lupus nephritis: a challenging cause of rapidly progressive crescentic glomerulonephritis

Renal Unit, Department of Medicine, Ramathibodi Hospital, Bangkok 10400, Thailand; ravsmmahidol.ac.th

P Chalermsanyakorn

Department of Medicine; Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

S Changsirikulchai

P Radinahamed

Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

The outcomes of 32 lupus patients with rapidly progressive crescentic glomerulonephritis were studied. Lupus nephritis accounted for 51.6% (32/62) of all patients with biopsy proven rapidly progressive crescentic glomerulonephritis during a six year observation period that includes 961 consecutive native kidney biopsies. Median entry serum creatinine was 221 imol/1. All patients received induction therapy with pulse methylprednisolone (n = 27) or intravenous cyclophos-phamide (n = 5). Maintenance therapies included prednisolone alone (group 1), prednisolone plus intermittent pulse intravenous cyclophosphamide (IVCY) (group 2) and prednisolone plus daily oral cytotoxic drugs (group 3). Twelve patients eventually had uremia. Seven further patients died of infection during therapy. One patient still had renal insufficiency and twelve patients had favorable clinical outcome (serum creatinine < 200 lmol/ 1). Patients in group 3 were more likely to have favorable clinical outcome than group 2 (P = 0.01; Fisher's exact test). Survival analysis found that the three year survival of ‘group 2 was 27.6% while that of ‘group 3’ was 83.3%. Our results suggest that lupus nephritis is not an infrequent cause of crescentic glomerulonephritis. Therapy with IVCY is not necessary associated with good outcome. Selected patients can be effectively treated with daily oral cytotoxic drugs as a reasonable alternative therapy.

Key Words: lupus nephritis • rapidly progressive crescentic glomerulonephritis • cyclophosphamide • survival analysis

Lupus, Vol. 9, No. 6, 424-428 (2000)
DOI: 10.1191/096120300678828587


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?